Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.87 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.87 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | MLNR | O43193 | 1/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967638 | 0.93 | SLC6A4 (1.00) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| SCHEMBL3359634 | 0.93 | SLC6A4 (1.00) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Hydrochloric Acid SCHEMBL4413256 | 0.92 | SLC6A4 (0.98) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Phosphoric Acid SCHEMBL3624 | 0.92 | SLC6A4 (0.87) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Oxalic Acid SCHEMBL3562 | 0.85 | SLC6A2 (0.63) | SLC6A4SLC6A2CACNA2D1HTR1A | |
| Duloxetine SCHEMBL308488 | 0.82 | SLC6A2 (0.87) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Duloxetine SCHEMBL3896385 | 0.82 | SLC6A2 (0.87) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| Duloxetine SCHEMBL3335 | 0.82 | SLC6A2 (0.87) | SLC6A4SLC6A2CACNA2D1SLC6A3MLNR | |
| SCHEMBL2722680 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP1A2CYP3A4 | |
| SCHEMBL20292549 | 0.81 | CACNA2D1 (1.00) | SLC6A4SLC6A2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4956388-A | ANTIDEPRESSANTS, ANTIANXIETY, TREATMENT OF OBESITY, ADDICTION TO SMOKING AND ALCOHOL | ELI LILLY AND COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |